Vanguard Group Inc. Grows Position in Anavex Life Sciences Corp. $AVXL

Key Points

• Vanguard Group Inc. increased its stake in Anavex Life Sciences Corp. by 4.7%, now owning 4,902,246 shares valued at approximately $42 million.
• Anavex Life Sciences recently experienced mixed analyst ratings, with two firms maintaining a "buy" rating and target prices of $42.00 and $46.00, while another firm downgraded their rating to "sell."
• As of now, 31.55% of Anavex Life Sciences stock is owned by institutional investors, indicating strong interest from large financial entities.

Vanguard Group Inc. raised its stake in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 4.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,902,246 shares of the biotechnology company's stock after purchasing an additional 221,802 shares during the period. Vanguard Group Inc. owned 5.74% of Anavex Life Sciences worth $42,061,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the business. Vermillion Wealth Management Inc. acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $34,000. Tower Research Capital LLC TRC raised its stake in shares of Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after buying an additional 1,708 shares during the period. 180 Wealth Advisors LLC purchased a new stake in shares of Anavex Life Sciences during the first quarter worth approximately $121,000. KLP Kapitalforvaltning AS purchased a new stake in shares of Anavex Life Sciences during the first quarter worth approximately $141,000. Finally, Yukon Wealth Management Inc. purchased a new stake in Anavex Life Sciences in the 1st quarter valued at $147,000. Hedge funds and other institutional investors own 31.55% of the company's stock.

Anavex Life Sciences Stock Up 4.6%

NASDAQ:AVXL traded up $0.42 during mid-day trading on Monday, reaching $9.64. 881,720 shares of the stock were exchanged, compared to its average volume of 883,327. The company has a 50 day simple moving average of $10.54 and a 200-day simple moving average of $9.27. The stock has a market capitalization of $827.98 million, a P/E ratio of -16.91 and a beta of 0.83. Anavex Life Sciences Corp. has a 1 year low of $4.93 and a 1 year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). As a group, research analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on AVXL shares. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday, August 27th. Wall Street Zen lowered Anavex Life Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 23rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a report on Friday, August 22nd. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $44.00.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.